LON:MPH Mereo BioPharma Group plc (MPH.L) Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mereo BioPharma Group plc (MPH.L) Please log in to your account or sign up in order to add this asset to your watchlist. GBX 26.50 -0.50 (-1.85%) (As of 12/17/2020) Add Compare Share Today's Range 26▼ 26.5050-Day Range 26.50▼ 26.5052-Week Range 13▼ 60Volume49,264 shsAverage Volume333,975 shsMarket Capitalization£89.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsInsider TradesHeadlines Mereo BioPharma Group plc (MPH.L) MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.33 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Mereo BioPharma Group plc (MPH.L). Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for MPH. Previous Next 0.0 Dividend Strength Dividend YieldMereo BioPharma Group plc (MPH.L) does not currently pay a dividend.Dividend GrowthMereo BioPharma Group plc (MPH.L) does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MPH. Previous Next 1.7 News and Social Media Coverage News SentimentMereo BioPharma Group plc (MPH.L) has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Mereo BioPharma Group plc (MPH.L) this week, compared to 0 articles on an average week.MarketBeat Follows4 people have added Mereo BioPharma Group plc (MPH.L) to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mereo BioPharma Group plc (MPH.L) insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Mereo BioPharma Group plc (MPH.L) is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mereo BioPharma Group plc (MPH.L) is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMereo BioPharma Group plc (MPH.L) has a P/B Ratio of 3.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mereo BioPharma Group plc (MPH.L) and its competitors with MarketBeat's FREE daily newsletter. Email Address About Mereo BioPharma Group plc (MPH.L) (LON:MPH) StockMereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfect; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.Read More MPH Stock News HeadlinesJuly 5, 2022 | finance.yahoo.comMereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price RequirementJune 19, 2022 | americanbankingnews.comMereo BioPharma Group plc (MPH.L) (LON:MPH) Shares Cross Below 50-Day Moving Average of $26.50June 17, 2022 | finance.yahoo.comWhy Mereo BioPharma Shares Are Jumping TodayJune 17, 2022 | seekingalpha.comMereo BioPharma: Activist Pressure In A Net-Net BiopharmaMay 17, 2022 | markets.businessinsider.comAlliance Pharma To Acquire LGC's Bio-analytical Business Arm For Undisclosed SumMay 11, 2022 | finance.yahoo.comARTRYA SIGNS FIRST U.S. HOSPITAL CLINICAL PARTNERSHIP WITH HUNTSVILLE HEART CENTERMay 11, 2022 | finance.yahoo.comNew Research Continues to Reinforce Effectiveness of Massage Therapy for Relief of Chronic PainMay 7, 2022 | tmcnet.comMereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from "ASTRAEUS" Phase 2 Study of AlvelestatJune 2, 2021 | msn.comBRIEF-Mereo Biopharma Announces Positive Desmosine Biomarker Data From An Interim Analysis Of An Investigator Initiated Study Of Alvelestat In Bronchiolitis Obliterans Syndrome ...March 31, 2021 | finance.yahoo.comMereo BioPharma Reports Full Year 2020 Financial Results and Recent HighlightsFebruary 18, 2021 | benzinga.comMereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare ConferenceFebruary 13, 2021 | bloomberg.comMereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise ofDecember 18, 2020 | benzinga.comMid-Day Market Update: Crude Oil Rises 1.5%; Mesoblast Shares PlungeDecember 18, 2020 | nasdaq.comStock Alert: Mereo BioPharma Soars 50% On Collaboration Deal With UltragenyxDecember 18, 2020 | finance.yahoo.comUltragenyx (RARE), Mereo Ink Deal for Bone Disease CandidateDecember 17, 2020 | finance.yahoo.comMereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis ImperfectaDecember 17, 2020 | finance.yahoo.comUltragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis ImperfectaDecember 15, 2020 | finance.yahoo.comMereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on agreements with Silicon Valley Bank and Kreos CapitalDecember 8, 2020 | finance.yahoo.comIs MREO A Good Stock To Buy Now?November 10, 2020 | finance.yahoo.comMereo BioPharma to Present at the Stifel 2020 Virtual Healthcare ConferenceOctober 19, 2020 | markets.businessinsider.comMereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)October 14, 2020 | au.finance.yahoo.comMEREO BIOPHARMA GROUP LTD (MAH.MU)September 9, 2020 | finanznachrichten.deBioNTech SE: Biopharma Leaders Unite to Stand with ScienceAugust 26, 2020 | nasdaq.comMereo Begins Phase 1b/2 Trial To Evaluate Alvelestat In COVID-19-associated Respiratory DiseaseJune 30, 2020 | finance.yahoo.comMereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and DevelopmentSee More Headlines Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:MPH CUSIPN/A CIKN/A Webmereobiopharma.com Phone44 33 3023 7300FaxN/AEmployees50Year FoundedN/ACompany Calendar Last Earnings9/29/2020Today7/07/2022Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio164.26 Current Ratio2.98 Quick Ratio2.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 17.12 per share Price / Cash Flow1.55 Book ValueGBX 7.20 per share Price / Book3.68Miscellaneous Outstanding Shares338,713,984Free FloatN/AMarket Cap£89.76 million OptionableNot Optionable BetaN/A Mereo BioPharma Group plc (MPH.L) Frequently Asked Questions How has Mereo BioPharma Group plc (MPH.L)'s stock price performed in 2022? Mereo BioPharma Group plc (MPH.L)'s stock was trading at GBX 26.50 on January 1st, 2022. Since then, MPH shares have increased by 0.0% and is now trading at GBX 26.50. View the best growth stocks for 2022 here. How were Mereo BioPharma Group plc (MPH.L)'s earnings last quarter? Mereo BioPharma Group plc (MPH.L) (LON:MPH) posted its quarterly earnings results on Tuesday, September, 29th. The company reported ($105.00) earnings per share for the quarter. View Mereo BioPharma Group plc (MPH.L)'s earnings history. Who are Mereo BioPharma Group plc (MPH.L)'s key executives? Mereo BioPharma Group plc (MPH.L)'s management team includes the following people: Dr. Denise Scots-Knight, Co-Founder, CEO & Exec. Director (Age 61, Pay $751.37k)Mr. Charles Sermon, Co-Founder, Gen. Counsel & Company Sec. (Age 51, Pay $545.68k)Dr. Alastair MacKinnon, Co-Founder & Chief Medical Officer (Age 50, Pay $540.12k)Mr. John Richard, Co-Founder & Head of Corp. Devel. (Age 63, Pay $512.99k)Mr. Michael Stephen Wyzga MBA, Interim CFO & Exec. Director (Age 65, Pay $27.59k)Ms. Alexandra Hughes-Wilson, Head of Patient Access & Commercial Planning (Age 49, Pay $265.93k)Ms. Jill Henrich, US Site Head & Sr. VP of Regulatory Affairs (Age 57, Pay $286.93k)Dr. John A. Lewicki, Chief Scientific Officer (Age 68)Dr. Fiona Bor, Head of Intellectual PropertyMr. Ian Hodgson, Head of Clinical Operations Who are some of Mereo BioPharma Group plc (MPH.L)'s key competitors? Some companies that are related to Mereo BioPharma Group plc (MPH.L) include ProMetic Life Sciences (PLI), Precigen (PGEN), Horizon Discovery Group plc (HZD.L) (HZD), Theratechnologies (TH), VIVO Cannabis (ABCN), Emblem (EMC), Verona Pharma plc (VRP.L) (VRP), Inventiva (IVA), Redx Pharma (REDX), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), BriaCell Therapeutics (BCT), Agronomics (ANIC), Arix Bioscience (ARIX) and Circassia Group (CIR). View all of MPH's competitors. What other stocks do shareholders of Mereo BioPharma Group plc (MPH.L) own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group plc (MPH.L) investors own include Enanta Pharmaceuticals (ENTA), Advanced Micro Devices (AMD), American Tower (AMT), Inovio Pharmaceuticals (INO), Micron Technology (MU), Tesla (TSLA), Amgen (AMGN), ARMOUR Residential REIT (ARR), Arena Pharmaceuticals (ARNA) and Ardelyx (ARDX). What is Mereo BioPharma Group plc (MPH.L)'s stock symbol? Mereo BioPharma Group plc (MPH.L) trades on the London Stock Exchange (LON) under the ticker symbol "MPH." How do I buy shares of Mereo BioPharma Group plc (MPH.L)? Shares of MPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Mereo BioPharma Group plc (MPH.L)'s stock price today? One share of MPH stock can currently be purchased for approximately GBX 26.50. How much money does Mereo BioPharma Group plc (MPH.L) make? Mereo BioPharma Group plc (MPH.L) (LON:MPH) has a market capitalization of £89.76 million. How many employees does Mereo BioPharma Group plc (MPH.L) have? Mereo BioPharma Group plc (MPH.L) employs 50 workers across the globe. How can I contact Mereo BioPharma Group plc (MPH.L)? Mereo BioPharma Group plc (MPH.L)'s mailing address is 1 Cavendish Place, LONDON, W1G 0QF, United Kingdom. The official website for Mereo BioPharma Group plc (MPH.L) is mereobiopharma.com. The company can be reached via phone at 44 33 3023 7300. This page (LON:MPH) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
